| 前收市價 | 2.2300 |
| 開市 | 1.8500 |
| 買盤 | 1.6000 |
| 賣出價 | 2.6000 |
| 拍板 | 7.50 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 1.8500 - 3.6700 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 8 |
ZacksVir Biotechnology (VIR) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
BenzingaWhy Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta. Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with elebsiran was generally well tolerated. Participants achieved high virologic response rates at weeks 12 and 24, durable virologic response through 48 weeks, and high alanine transaminase (ALT) normal
ZacksWall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
